石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

休市中 04-02 16:08:21

9.710

+0.090

+0.94%

最高9.880	最低9.490	成交量1.01亿
今开9.620	昨收9.620	日振幅4.05%
总市值1,119亿	流通市值1,119亿	总股本115.22亿
成交额9.78亿	换手率0.88%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":9.71,"timestamp":1775117301003,"preClose":9.62,"halted":0,"volume":101003222,"delay":0,"changeRate":0.009355509355509526,"floatShares":11522000000,"shares":11522000000,"eps":0.3865348841583848,"marketStatus":"休市中","change":0.09,"latestTime":"04-02 16:08:21","open":9.62,"high":9.88,"low":9.49,"amount":978380451,"amplitude":0.040541,"askPrice":9.71,"askSize":290000,"bidPrice":9.7,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":0.3865348841583848,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":9.62,"dividendRate":0.024696,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.6706955733490014,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":false,"expireDate":1779897600000,"strike":"10.00","timestamp":1775107918441,"price":1.03,"volume":220,"amount":453200,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.6068,"impliedVolPercentile":0.7602},"requestUrl":"/m/hq/s/01093/wiki","defaultTab":"wiki","newsList":[{"id":"2624652733","title":"石药全面入主后，这家上市公司董事长换人","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652733","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624652733?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:13","pubTimestamp":1775214780,"startTime":"0","endTime":"0","summary":"01董事会换届落定石药系全面入主4月3日，ST景峰发布公告，已完成第九届董事会换届选举，同时聘任相关高级管理人员。ST景峰第九届董事会由9名董事组成，其中非独立董事6名，独立董事3名。从资本市场来看，收购方为获得稳固控股权，并以经营改善等为目标入主上市公司时，更换董事长、派驻核心管理团队是实现有效管控的必要手段。石药系作为战略入主方，此次更换核心掌舵人，为后续业务经营奠定基础。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-04-03/doc-inhtfrev3663468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","SG9999004220.SGD","LU1807302812.USD","LU1226287529.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1226288170.HKD","LU0140636845.USD","IE0008369823.USD","LU1226287792.SGD","HK0000165453.HKD","LU1152091754.HKD","LU1226288253.USD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1951186391.HKD","01093","LU1960683339.HKD","LU2039709279.SGD","LU0315179316.USD","IE0008368742.USD","LU0072913022.USD","LU1993786604.SGD","LU0326950275.SGD","BK1521","LU0880133367.SGD","IE00BZ08YR35.GBP","LU0067412154.USD","IE00B543WZ88.USD","LU1152091168.USD","LU1813983027.USD","BK1191","IE00BZ08YS42.EUR","LU1328277881.USD","LU0314109678.HKD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509138","title":"石药集团(01093)授出合共946.2万份受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509138","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624509138?lang=zh_cn&edition=full","pubTime":"2026-04-02 20:31","pubTimestamp":1775133064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，于2026年4月2日，公司根据2018年股份奖励计划向集团488名获选参与者无偿授出合共946.2万份受限制股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU0140636845.USD","LU1328277881.USD","LU1993786604.SGD","LU0067412154.USD","LU0314109678.HKD","LU1226288253.USD","IE0008369823.USD","BK1521","LU1008478684.HKD","IE00B5MMRT66.SGD","IE0008368742.USD","BK1191","LU0880133367.SGD","LU0326950275.SGD","LU1226287792.SGD","IE00B031HY20.USD","LU0315179316.USD","BK1515","LU0072913022.USD","LU1807302812.USD","LU1226287529.USD","LU0501845795.SGD","LU1226287875.USD","01093","IE00B543WZ88.USD","SG9999004220.SGD","LU1960683339.HKD","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1813983027.USD","LU1951186391.HKD","LU1226288170.HKD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138259979","title":"石药集团3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1138259979","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138259979?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:06","pubTimestamp":1775037962,"startTime":"0","endTime":"0","summary":"2026年4月1日，石药集团（股票代码：01093）披露2026年3月股份变动月报表，报告期截至2026年3月31日。\n石药集团于报告期内，无新增发行股份、无购回或注销行为。普通股的已发行股份数量在本月初和本月末均维持11,522,451,732股，注册股本亦未发生变化。\n期权方面，“2015年购股权计划”延续此前安排，期末可行使的股份期权数量与上月一致，均为1,300,000份。本月并未因该期权计划新增发行股份或转让库存股。\n公司表示，其已符合香港联交所关于公众持股量的相关规定，并持续遵守香港联交所《上市规则》及适用法律。根据公告信息，本次月报由公司秘书罗泰安签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623139583","title":"石药集团(01093)：安尼妥单抗联合多西他赛(白蛋白结合型)新辅助治疗HER2+乳腺癌Ⅲ期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2623139583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623139583?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:06","pubTimestamp":1774955167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本公司附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司合作开发的安尼妥单抗注射液，在联合集团自主研发的注射用多西他赛用于HER2阳性早期或局部晚期乳腺癌新辅助治疗的III期临床研究中，达到预先设定的总体病理完全缓解率的主要终点，结果具有显著的统计学和临床意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：安尼妥单抗联合多西他赛(白蛋白结合型)新辅助治疗HER2+乳腺癌Ⅲ期研究达到主要终点","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","IE00B031HY20.USD","BK1515","LU1993786604.SGD","LU1152091754.HKD","LU1008478684.HKD","LU1960683339.HKD","IE00BZ08YR35.GBP","SG9999004220.SGD","LU0140636845.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1328277881.USD","01093","LU0326950275.SGD","LU0501845795.SGD","LU0315179316.USD","LU1813983027.USD","LU1807302812.USD","LU1152091168.USD","LU2039709279.SGD","LU0314109678.HKD","LU1226288253.USD","BK1521","IE00B543WZ88.USD","BK1191","IE0008368742.USD","LU1226287875.USD","LU1226288170.HKD","LU1226287529.USD","LU0067412154.USD","HK0000165453.HKD","IE0008369823.USD","LU1226287792.SGD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147944429","title":"石药集团安贝尼妥单抗联合多西他赛治疗HER2阳性乳腺癌III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1147944429","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147944429?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:03","pubTimestamp":1774954985,"startTime":"0","endTime":"0","summary":"石药集团宣布，其研发的安贝尼妥单抗（Anbenitamab）联合多西他赛（Docetaxel）治疗HER2阳性乳腺癌的III期临床研究已成功达到预设的主要终点。\n该研究旨在评估联合疗法在HER2阳性乳腺癌患者中的疗效与安全性。数据显示，安贝尼妥单抗与多西他赛联用显著改善了患者的无进展生存期，凸显了该方案在这一难治性乳腺癌亚型中的治疗潜力。\n此次III期研究的积极结果，为安贝尼妥单抗的后续注册申报提供了关键支持，有望为HER2阳性乳腺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","IE0008368742.USD","HK0000165453.HKD","BK1521","LU1813983027.USD","IE00B543WZ88.USD","SG9999004220.SGD","LU0501845795.SGD","LU1960683339.HKD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU1226287875.USD","IE00B031HY20.USD","LU2039709279.SGD","LU1951186391.HKD","LU0880133367.SGD","LU0067412154.USD","LU1328277881.USD","BK1191","01093","LU1152091168.USD","LU1993786604.SGD","LU1226287792.SGD","IE0008369823.USD","LU0072913022.USD","LU1152091754.HKD","LU0315179316.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU0326950275.SGD","LU0314109678.HKD","LU0140636845.USD","LU1226287529.USD","BK1515","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371082","title":"交银国际：上调石药集团(01093)目标价至8.7港元 维持“中性”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371082?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:16","pubTimestamp":1774926993,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，上调石药集团(01093)目标价至8.7港元，认为当前估值合理，维持“中性”评级。该行调整对该公司2026-2027年盈利预测，基于授权费收入确认节奏的最新预测，因此上调目标价。受授权费收入确认节奏的影响，2025年第四季业绩未达预期，但成药产品销售持续录得边际改善。2026年，新品销售放量及大额授权费收入将成为绩效核心驱动力。公司在研发和出海上保持高效执行力，推动创新管线价值快速兑现，但核心业务或尚需时日走出监管和竞争压力的影响，因此维持“中性”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623362830","title":"两大外资机构齐声看多基石药：最高目标价看至20港元 CS2009成核心看点","url":"https://stock-news.laohu8.com/highlight/detail?id=2623362830","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623362830?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:41","pubTimestamp":1774834860,"startTime":"0","endTime":"0","summary":"　　近期，多家国际投资机构发布研究报告，对基石药业-B核心在研产品CS2009的临床数据及其商业化前景给予积极评价。其中，杰富瑞维持“买入”评级，目标价20港元；高盛亦维持“买入”评级，目标价9.44港元。研报均指出，PD-1/VEGF/CTLA-4三特异性抗体CS2009在多项适应症中展现出突出的疗效与良好的安全性，有望成为公司未来对外授权及价值重估的重要驱动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-03-30/doc-inhstpie9821175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622846221","title":"港股收评：恒指涨0.38% 科指涨0.35% 锂电池板块活跃 创新药概念股大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846221","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622846221?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:08","pubTimestamp":1774598880,"startTime":"0","endTime":"0","summary":"　　3月27日消息，港股三大指数集体上涨。截至收盘，恒生指数涨0.38%，报24951.88点，恒生科技指数涨0.35%，国企指数涨0.76%。盘面上，科网股涨跌不一，快手、小米涨超1%，哔哩哔哩跌超1%；创新药概念股大涨，石药集团涨超13%；锂电池板块涨幅居前，赣锋锂业涨超9%；商业航天板块跌幅居前，钧达股份跌超9%。近期创新药企业年报密集披露，龙头企业盈利能力显著提升，现金流丰沛，为长期研发投入筑牢根基。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e01cbc0eb24c402eed6076bf7c5c222","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-27/doc-inhsmhtw2154112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HHImain","01093","BK4585","BK4588","HSI","BK1574","513600","HSTECH","MCHmain","002460","02833"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622848308","title":"招银国际：石药集团对外授权可成收入持续增长引擎 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622848308","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622848308?lang=zh_cn&edition=full","pubTime":"2026-03-27 14:48","pubTimestamp":1774594080,"startTime":"0","endTime":"0","summary":"　　招银国际发布研报称，考虑到2025年成药销售表现较弱，调整对其盈利预测，将石药集团目标价由13.93港元下调至13.05港元，此现金流折现率作估值，维持“买入”评级。招银国际料石药2026年至2028年纯利各为57.06亿、56.2亿及69.7亿人民币，对比2025年为38.76亿人民币。　　该行表示，扣除授权费收入后，石药集团2025年成药销售同比跌20.8%，主要受医院处方管控及带量采购持续影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-03-27/doc-inhsmhtr9520602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184490371","title":"港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184490371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184490371?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:05","pubTimestamp":1774587950,"startTime":"0","endTime":"0","summary":"信达生物涨超7%，君实生物、诺诚健华涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","01093","01801","06127","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622268819","title":"美银证券：降石药集团(01093)目标价至8港元 评级“跑输大市”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622268819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622268819?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:58","pubTimestamp":1774580303,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，石药集团(01093)去年入账总收入同比跌10.4%至260亿元人民币(下同)，净利润同比跌10.3%至39亿元。该行预料石药今年合作总收入逾100亿元，同时对石药今年至2028年各年收入预测作调整，分别升0.4%、降4.1%及降4.1%，各年每股盈测各下调0.4%、7.1%及22.3%，其目标价由9.1港元下调至8港元，维持其评级为“跑输大市”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420230.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127295656","title":"异动解读 | 主席大手笔增持，石药集团盘中大涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127295656","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127295656?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:54","pubTimestamp":1774576492,"startTime":"0","endTime":"0","summary":"石药集团今日盘中大涨5.15%，引起了市场的广泛关注。消息面上，公司执行董事兼主席蔡东晨于前一交易日，在场内以每股均价约8.36港元的价格，增持了4940万股公司股份，涉及资金约4.13亿港元。此次增持后，其持股比例由25.31%上升至25.74%。公司内部人士，尤其是董事会主席的大规模增持行为，通常被视为对公司未来发展和当前估值充满信心的强烈信号。这一积极的内部动作，有效提振了市场情绪，成为推动股价在今日盘中显著走强的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852075","title":"董事会主席蔡东晨增持石药集团(01093)4940万股 每股作价约8.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852075","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622852075?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:56","pubTimestamp":1774522601,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，3月26日，董事会主席蔡东晨增持石药集团(01093)4940万股，每股作价8.3612港元，总金额约为4.13亿港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260326/20260326185722_77382.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260326/20260326185722_77382.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"董事会主席蔡东晨增持石药集团(01093)4940万股 每股作价约8.36港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BZ08YT58.USD","01093","LU0315179316.USD","LU2039709279.SGD","LU0072913022.USD","SG9999004220.SGD","LU1226287792.SGD","LU1226288253.USD","LU0326950275.SGD","IE0008368742.USD","LU0501845795.SGD","LU1960683339.HKD","LU1226287529.USD","LU1008478684.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU0880133367.SGD","BK1521","LU0067412154.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU0140636845.USD","BK1515","HK0000165453.HKD","LU1813983027.USD","LU1226288170.HKD","IE00B031HY20.USD","LU0314109678.HKD","LU1807302812.USD","LU1226287875.USD","LU1152091754.HKD","BK1191","IE0008369823.USD","LU1993786604.SGD","LU1152091168.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622583277","title":"富瑞：升石药集团(01093)目标价至7.2港元 维持“跑输大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2622583277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622583277?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:59","pubTimestamp":1774511963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，富瑞发布研报称，石药集团(01093)去年业绩仍面临压力，全年收入同比跌10%至260亿元人民币，逊预期。虽然管理层预期成品药业务今年可恢复正增长，但市场关注潜在带量采购(VBP)风险，包括盐酸伊立替康脂质体注射液可能被纳入全国VBP。该行维持石药“跑输大市”评级，但目标价由5.9港元升至7.2港元。富瑞认为，管理阶层预期带量采购的不利因素将在今年持续。虽然业务拓展(BD)是关键，但市场仍将股价押注预付款憧憬，随着预期上调，失望的风险正在上升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622745835","title":"花旗：降石药集团(01093)目标价至11.5港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622745835","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622745835?lang=zh_cn&edition=full","pubTime":"2026-03-26 13:52","pubTimestamp":1774504358,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，石药集团去年收入达260亿元人民币，同比跌10%，纯利达39亿元人民币，同比跌10%; 销售费用同比下降25%至65亿元人民币，研发成本增加12%至58亿元人民币。该行将公司今年和明年收入预测下调1%及2%，每股盈利预测各下调14%及15%，其目标价由12.1港元下调至11.5港元，维持“买入”评级。EGFR抗体偶联药物用于二线EGFR突变型非小细胞肺癌的潜在生物制品许可申请预计在2026年底前获得批准。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622960079","title":"石药集团(01093)采纳2026年股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2622960079","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622960079?lang=zh_cn&edition=full","pubTime":"2026-03-25 21:12","pubTimestamp":1774444334,"startTime":"0","endTime":"0","summary":"于2024年5月21日修订2018年股份奖励计划的条款后，董事会仅可指示受托人于市场上购买现有股份，以满足根据2018年股份奖励计划授予的股份奖励。自2018年采纳2018年股份奖励计划起，尚未透过发行或配发新股份的方式满足根据该计划授予的股份奖励。2018年股份奖励计划将继续具有十足效力及效用，直至其于2028年8月19日届满为止，且不影响2018年股份奖励计划下获选参与者的现有权利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","BK1191","LU0880133367.SGD","LU1226287875.USD","BK1515","IE00BZ08YS42.EUR","LU1226287792.SGD","IE00B031HY20.USD","LU1807302812.USD","IE00BZ08YT58.USD","LU1152091168.USD","LU1328277881.USD","LU1152091754.HKD","LU1993786604.SGD","IE00B543WZ88.USD","LU0314109678.HKD","SG9999004220.SGD","LU2039709279.SGD","IE0008368742.USD","LU0072913022.USD","LU1951186391.HKD","LU1960683339.HKD","IE00B5MMRT66.SGD","IE0008369823.USD","HK0000165453.HKD","LU1226288253.USD","LU1226287529.USD","LU0067412154.USD","LU1008478684.HKD","LU1813983027.USD","LU1226288170.HKD","01093","LU0501845795.SGD","IE00BZ08YR35.GBP","BK1521","LU0315179316.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622419410","title":"石药集团(01093)将于7月15日派发末期股息每股0.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622419410","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622419410?lang=zh_cn&edition=full","pubTime":"2026-03-25 13:08","pubTimestamp":1774415283,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，该公司将于2026年7月15日派发末期股息每股0.15港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ba25b1588c8e6692f0294260f00552f3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","IE00BZ08YT58.USD","LU1226288253.USD","BK1191","IE00B031HY20.USD","LU1152091168.USD","BK1521","LU0501845795.SGD","LU1152091754.HKD","LU1328277881.USD","HK0000165453.HKD","LU0880133367.SGD","BK4585","LU1226287792.SGD","LU0072913022.USD","01093","LU1813983027.USD","LU0140636845.USD","LU1960683339.HKD","LU0314109678.HKD","IE0008369823.USD","IE0008368742.USD","LU1993786604.SGD","LU0315179316.USD","LU2039709279.SGD","LU1807302812.USD","LU1226288170.HKD","VIG","SG9999004220.SGD","LU0067412154.USD","BK1515","IE00B543WZ88.USD","BK4588","LU1226287529.USD","IE00BZ08YR35.GBP","LU1008478684.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622041556","title":"石药集团2025年业绩：收入降10.4%，归母净利润降10.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041556","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622041556?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:37","pubTimestamp":1774413420,"startTime":"0","endTime":"0","summary":"3月25日，石药集团（01093）发布截至2025年12月31日止年度之全年业绩。公司及其附属公司收入总额为260.06亿元，较2024年的290.09亿元减少10.4%，主要由于多美素?和津优力?两款产品被纳入集中采购。此外，本公司股东应占溢利为38.82亿元，同比下降10.3%。基本每股盈利为33.98分，较上年下降7.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"ba25b1588c8e6692f0294260f00552f3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253683830452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804943","title":"石药集团(01093)2025年股东溢利同比减少10.3% 拟派末期股息15港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804943","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622804943?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:27","pubTimestamp":1774412847,"startTime":"0","endTime":"0","summary":"金吾财讯 | 石药集团 公告公布，截至2025年12月31日止年度，公司股东应占溢利38.82亿元，同比减少10.3%；每股基本盈利33.98分。拟派末期股息15港仙，全年股息29港仙。期内，集团收入总额260.06亿元，同比减少10.4%，主要是由于多美素和津优力两款产品被纳入集中采购所致。其中，成药业务收入205.84亿元，同比减少13.3%；原料产品业务收入36.57亿元，同比增长2.1%；功能食品及其他收入17.65亿元，同比增长4.5%。期内，毛利170.59亿元，同比减少15.96%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZDU3MjExMzhjMmFmNDFjMDg5MzczN2Y3MTNmMTc0NDI4NjU0MjU0ODcxMjc5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDU3MjExMzhjMmFmNDFjMDg5MzczN2Y3MTNmMTc0NDI4NjU0MjU0ODcxMjc5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BZ08YS42.EUR","LU1226287792.SGD","BK4585","BK1521","LU1993786604.SGD","LU1226287875.USD","LU1807302812.USD","LU1152091754.HKD","LU1226288170.HKD","LU1008478684.HKD","BK1515","LU1328277881.USD","LU0067412154.USD","BK1191","LU0314109678.HKD","LU0501845795.SGD","IE00B031HY20.USD","LU1960683339.HKD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0315179316.USD","LU1152091168.USD","IE00B5MMRT66.SGD","LU2039709279.SGD","LU0140636845.USD","LU0072913022.USD","LU0326950275.SGD","01093","LU1226287529.USD","LU0880133367.SGD","HK0000165453.HKD","VIG","SG9999004220.SGD","IE0008368742.USD","LU1226288253.USD","IE00B543WZ88.USD","IE0008369823.USD","LU1813983027.USD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158674498","title":"石药集团将于2026年7月15日派发末期股息每股0.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158674498","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158674498?lang=zh_cn&edition=full","pubTime":"2026-03-25 12:21","pubTimestamp":1774412462,"startTime":"0","endTime":"0","summary":"石药集团(01093)\n根据最新公告，公司董事会宣布截至2025年12月31日止年度的末期股息为每股0.15港元。该派息方案尚待股东于2026年5月28日股东大会上批准。\n股息派发的除净日为2026年6月24日，股东如需符合派息资格，须于2026年6月25日16时30分前递交过户文件。公司将于2026年6月26日至6月29日暂停办理股份过户登记，并于2026年6月29日为记录日期。股息预计于2026年7月15日派发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ba25b1588c8e6692f0294260f00552f3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.19},{"period":"1month","weight":0.0531},{"period":"3month","weight":0.145},{"period":"6month","weight":0.0163},{"period":"1year","weight":0.8058},{"period":"ytd","weight":0.1518}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.625,"avgChangeRate":0.062229},{"month":5,"riseRate":0.612903,"avgChangeRate":0.047434},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}